Increasing Hospital-Acquired Infection (HAI) and Increasing Government Regulations to Control Hospital Infections is Driving the Global Levofloxacin Market

The global levofloxacin market is anticipated to grow at a considerable CAGR of 5.5% during the forecast period (2022-2028). A major element driving market expansion is hospital-acquired infection (HAI). Pneumonia, bloodstream infection, surgical site infection, and urinary tract infection are among the most frequent hospital-acquired infections. Government regulations to prevent and control hospital infections, the need for disinfectants and disposable safety goods to reduce the danger of infectious microorganisms will increase. For instance, in 2018, the Centers for Disease Control and Prevention (CDC) estimates that roughly 2 million people in the US are infected with hospital-acquired diseases each year. The growth of the levofloxacin market is also driven by an increase in the global geriatric population, as well as an increase in the prevalence of chronic and infectious diseases. Lack of physical activity, unsanitary conditions, and lifestyle changes will all contribute to an increase in disease burden. As the immune system is less active in the elderly, they are more susceptible to infectious infections. As the prevalence of diseases rises, so will the demand for various bacterial and infection drugs, driving up the demand for levofloxacin products. Additionally, market is expected to increase as the prevalence of kidney infections rises, biotechnology and pharmaceutical companies engage more in R&D, and the demand for better treatment methods grows. Furthermore, favorable reimbursement policies, greater use, and considerable expenditures in the development of new technologies for disease treatment are expected to drive levofloxacin market growth throughout the forecast period.

Browse the full report description of “Global Levofloxacin Market Size, Share & Trends Analysis Report by Type (250MG, 500MG, and 750 MG), and by Application (Pneumonia, Skin Infection, Kidney Infection and Bladder Infection) Forecast Period (2022-2028)” at https://www.omrglobal.com/industry-reports/levofloxacin-market

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028

Segment Covered- 

• By Infection type
• By Distribution Channel

Regions Covered-

• North America
• Europe
• Asia-Pacific
• Rest of the World

Competitive Landscape- including Aden Healthcare, Allenge India Pharma, Alna Biotech Pvt. Ltd., Bestochem, DivineSavior.in and others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected regions and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global LevofloxacinMarket Report Segment

By Infection Type

• Pneumonia
• Skin Infection
• Kidney Infection
• Bladder Infection

By Distribution Channel

• Hospital Pharmacies 
• Retail Pharmacies
• Online Pharmacies

Global Levofloxacin Market Report Segment by Region

North America

• US
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Rest of Europe 

Asia-Pacific

• China
• India
• Japan
• South Korea
• Rest of Asia-Pacific 

Rest of the World

• Latin America 
• Middle East & Africa